Chantix, Champix (varenicline) is a small molecule pharmaceutical. Varenicline was first approved as Chantix on 2006-09-25. It has been approved in Europe to treat tobacco use cessation. The pharmaceutical is active against neuronal acetylcholine receptor subunit alpha-4. In addition, it is known to target neuronal acetylcholine receptor subunit alpha-3.
|Indication||tobacco use cessation|
|Drug Class||Nicotinic acetylcholine receptor partial agonists/agonists|